Your browser doesn't support javascript.
¿ Can COVID-19 exacerbate multiple sclerosis symptoms? A case series analysis.
Michelena, Gloria; Casas, Magdalena; Eizaguirre, María Bárbara; Pita, María Cecilia; Cohen, Leila; Alonso, Ricardo; Garcea, Orlando; Silva, Berenice A.
  • Michelena G; Hospital Militar Central Dr. Cosme Argerich, CABA, Argentina.
  • Casas M; Centro Universitario de Esclerosis Múltiple, Hospital JM Ramos Mejía, CABA, Argentina.
  • Eizaguirre MB; Centro Universitario de Esclerosis Múltiple, Hospital JM Ramos Mejía, CABA, Argentina.
  • Pita MC; Centro Universitario de Esclerosis Múltiple, Hospital JM Ramos Mejía, CABA, Argentina.
  • Cohen L; Centro Universitario de Esclerosis Múltiple, Hospital JM Ramos Mejía, CABA, Argentina.
  • Alonso R; Centro Universitario de Esclerosis Múltiple, Hospital JM Ramos Mejía, CABA, Argentina.
  • Garcea O; Centro Universitario de Esclerosis Múltiple, Hospital JM Ramos Mejía, CABA, Argentina.
  • Silva BA; Centro Universitario de Esclerosis Múltiple, Hospital JM Ramos Mejía, CABA, Argentina. Electronic address: bsilva@leloir.org.ar.
Mult Scler Relat Disord ; 57: 103368, 2022 Jan.
Article in English | MEDLINE | ID: covidwho-1517403
ABSTRACT

INTRODUCTION:

Peripheral inflammation can exacerbate pre-existing lesions in the Central Nervous System (CNS) in the context of neurodegenerative diseases, including Multiple Sclerosis (MS).

OBJECTIVE:

To analyze the clinical effect of COVID-19 infection, as a generator of peripheral inflammation, in a MS patients group.

METHODS:

A retrospective analysis of 400 medical records of MS patients from a referral center was carried out. MS patients who presented COVID-19 were surveyed about symptoms exacerbation type, duration and onset of exacerbation, previous vaccination against COVID-19 and MS severity. Clinical and demographic information from the medical records were included. Descriptive and inferential analysis were performed using the GraphPad Prism V6.

RESULTS:

41 patients were included, 61% (n = 25) reported neurological worsening, 9.7% (n = 4) as relapses, and 7.3% (n = 3) required corticosteroids. We found significant differences in the EDSS between patients who exacerbated their MS symptoms and those who did not (p = 0.03). When performing a multivariate regression analysis, we found that EDSS was independently associated with the presence of exacerbations of MS in the context of SARS-CoV2 infection (OR = 2.44, p = 0.022).

CONCLUSIONS:

This preliminary study suggests that COVID-19 infection could trigger exacerbations of MS symptoms. New studies are needed to elucidate the relationship between COVID-19 and MS.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 / Multiple Sclerosis Type of study: Observational study / Prognostic study Topics: Long Covid / Vaccines Limits: Humans Language: English Journal: Mult Scler Relat Disord Year: 2022 Document Type: Article Affiliation country: J.msard.2021.103368

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 / Multiple Sclerosis Type of study: Observational study / Prognostic study Topics: Long Covid / Vaccines Limits: Humans Language: English Journal: Mult Scler Relat Disord Year: 2022 Document Type: Article Affiliation country: J.msard.2021.103368